FDA’s Crawford Open To Discussing Independent Drug Safety Office
Executive Summary
FDA Acting Commissioner Lester Crawford is willing to consider making the Office of Drug Safety formally independent from drug review activities if he is confirmed as the agency's permanent leader
You may also be interested in...
A Brief But Memorable Tenure: Former US FDA Commissioner Lester Crawford Dies At 83
Crawford’s time as permanent FDA commissioner lasted less than three months and ended in scandal, but with that stint and his longer stretches as acting commissioner, he oversaw the agency through several historic moments that continue to influence the current regulatory environment.
FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals
Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals
FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals
Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals